Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jens Ebentheuer

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society|March 4, 2010
Substantia nigra echogenicity in progressive supranuclear palsyJens Ebentheuer, Monica Canelo, Ellen Trautmann, et al.
Movement Disorders Clinical Practice|October 27, 2018
Acute Levodopa Challenge Test in Patients with de novo Parkinson's Disease: Data from the DeNoPa CohortSebastian Schade, Friederike Sixel-Döring, Jens Ebentheuer, et al.
Acta Neuropathologica|May 3, 2014
Cutaneous neuropathy in Parkinson's disease: a window into brain pathologyKathrin Doppler, Sönke Ebert, Nurcan Uçeyler, et al.
CNS Drugs|November 16, 2017
Drug Safety Analysis in a Real-Life Cohort of Parkinson's Disease Patients with PolypharmacySaskia Müller-Rebstein, Claudia Trenkwalder, Jens Ebentheuer, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 16, 2015
Distinctive distribution of phospho-alpha-synuclein in dermal nerves in multiple system atrophyKathrin Doppler, Jessica Weis, Katharina Karl, et al.
Neuroscience Letters|November 15, 2012
Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjectsBrit Mollenhauer, Ellen Trautmann, Peggy Taylor, et al.
Journal of Parkinson'S Disease|November 1, 2021
Longitudinal Change and Progression Indicators Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale in Two Independent Cohorts with Early Parkinson's DiseaseMichael Bartl, Mohammed Dakna, Sebastian Schade, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|November 24, 2018
Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the De Novo Parkinson Cohort (DeNoPa)Brit Mollenhauer, Johannes Zimmermann, Friederike Sixel-Döring, et al.
Human Brain Mapping|January 20, 2011
Individual voxel-based subtype prediction can differentiate progressive supranuclear palsy from idiopathic Parkinson syndrome and healthy controlsNiels K Focke, Gunther Helms, Sebstian Scheewe, et al.
Neurology|May 11, 2016
Monitoring of 30 marker candidates in early Parkinson disease as progression markersBrit Mollenhauer, Johannes Zimmermann, Friederike Sixel-Döring, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Movement Disorders : Official Journal of the Movement Disorder Society|March 4, 2010
Substantia nigra echogenicity in progressive supranuclear palsyJens Ebentheuer, Monica Canelo, Ellen Trautmann, et al.
Movement Disorders Clinical Practice|October 27, 2018
Acute Levodopa Challenge Test in Patients with de novo Parkinson's Disease: Data from the DeNoPa CohortSebastian Schade, Friederike Sixel-Döring, Jens Ebentheuer, et al.
Acta Neuropathologica|May 3, 2014
Cutaneous neuropathy in Parkinson's disease: a window into brain pathologyKathrin Doppler, Sönke Ebert, Nurcan Uçeyler, et al.
CNS Drugs|November 16, 2017
Drug Safety Analysis in a Real-Life Cohort of Parkinson's Disease Patients with PolypharmacySaskia Müller-Rebstein, Claudia Trenkwalder, Jens Ebentheuer, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 16, 2015
Distinctive distribution of phospho-alpha-synuclein in dermal nerves in multiple system atrophyKathrin Doppler, Jessica Weis, Katharina Karl, et al.
Neuroscience Letters|November 15, 2012
Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjectsBrit Mollenhauer, Ellen Trautmann, Peggy Taylor, et al.
Journal of Parkinson'S Disease|November 1, 2021
Longitudinal Change and Progression Indicators Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale in Two Independent Cohorts with Early Parkinson's DiseaseMichael Bartl, Mohammed Dakna, Sebastian Schade, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|November 24, 2018
Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the De Novo Parkinson Cohort (DeNoPa)Brit Mollenhauer, Johannes Zimmermann, Friederike Sixel-Döring, et al.
Human Brain Mapping|January 20, 2011
Individual voxel-based subtype prediction can differentiate progressive supranuclear palsy from idiopathic Parkinson syndrome and healthy controlsNiels K Focke, Gunther Helms, Sebstian Scheewe, et al.
Neurology|May 11, 2016
Monitoring of 30 marker candidates in early Parkinson disease as progression markersBrit Mollenhauer, Johannes Zimmermann, Friederike Sixel-Döring, et al.
Pageof 2